COMP <GO>
RTSN vs COYA // GROSS PROFIT MARGIN
Retension Pharmaceuticals Inc. (NASDAQ) VS. Coya Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RTSN 1
— COYA 1
■ METRIC PARITY
LAST: $11.36 (-3.97%) • MKT CAP: $93.2M
gross-margins
—
LAST: $3.61 (-9.30%) • MKT CAP: $93.4M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RTSN VS. COYA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RTSN | COYA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -11.50% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 123.60% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 6.08 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 3/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.8 | 27.5 | +27.30 | RTSN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $93.2M | $93.4M | -$122.9K | COYA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RTSN REV | COYA REV | RTSN GROSS % | COYA GROSS % | RTSN FCF | COYA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $7.9M | — | — | — | -$10.7M |
| FY 2024 | — | $3.6M | — | — | — | -$10.3M |
| FY 2023 | — | $6.0M | — | — | — | -$11.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RTSN // BETA —
COYA // BETA —